These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 18056833)
1. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Maidment ID; Fox CG; Boustani M; Rodriguez J; Brown RC; Katona CL Ann Pharmacother; 2008 Jan; 42(1):32-8. PubMed ID: 18056833 [TBL] [Abstract][Full Text] [Related]
2. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Gauthier S; Wirth Y; Möbius HJ Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444 [TBL] [Abstract][Full Text] [Related]
3. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Gauthier S; Loft H; Cummings J Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838 [TBL] [Abstract][Full Text] [Related]
4. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial. Cumbo E; Ligori LD J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733 [TBL] [Abstract][Full Text] [Related]
5. Behavioral effects of current Alzheimer's disease treatments: a descriptive review. Cummings JL; Mackell J; Kaufer D Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950 [TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598 [TBL] [Abstract][Full Text] [Related]
7. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Grossberg GT; Pejović V; Miller ML; Graham SM Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105 [TBL] [Abstract][Full Text] [Related]
8. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Diehl-Schmid J; Förstl H; Perneczky R; Pohl C; Kurz A Int J Geriatr Psychiatry; 2008 Jul; 23(7):754-9. PubMed ID: 18213609 [TBL] [Abstract][Full Text] [Related]
9. Memantine in the treatment of dementia. Maggiore C; Locatelli L; Grandi FC; Pizzolato G; Neuroepidemiology; 2007; 28(2):118-9. PubMed ID: 17409774 [No Abstract] [Full Text] [Related]
10. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Wilkinson D; Andersen HF Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761 [TBL] [Abstract][Full Text] [Related]
11. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Matsumoto N; Ikeda M; Fukuhara R; Shinagawa S; Ishikawa T; Mori T; Toyota Y; Matsumoto T; Adachi H; Hirono N; Tanabe H Dement Geriatr Cogn Disord; 2007; 23(4):219-24. PubMed ID: 17299264 [TBL] [Abstract][Full Text] [Related]
12. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease. Okahara K; Ishida Y; Hayashi Y; Inoue T; Tsuruta K; Takeuchi K; Yoshimuta H; Kiue K; Ninomiya Y; Kawano J; Yoshida K; Noda S; Tomita S; Fujimoto M; Hosomi J; Mitsuyama Y Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):532-6. PubMed ID: 20170698 [TBL] [Abstract][Full Text] [Related]
13. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Beier MT Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151 [TBL] [Abstract][Full Text] [Related]
14. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies. Tariot PN J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847 [TBL] [Abstract][Full Text] [Related]
15. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study. Paleacu D; Barak Y; Mirecky I; Mazeh D Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256 [TBL] [Abstract][Full Text] [Related]
16. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine. Rüther E; Glaser A; Bleich S; Degner D; Wiltfang J Pharmacopsychiatry; 2000 May; 33(3):103-8. PubMed ID: 10855461 [TBL] [Abstract][Full Text] [Related]
17. Memantine for dementia? Drug Ther Bull; 2003 Oct; 41(10):73-6. PubMed ID: 14593973 [TBL] [Abstract][Full Text] [Related]
18. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Görtelmeyer R; Erbler H Arzneimittelforschung; 1992 Jul; 42(7):904-13. PubMed ID: 1418054 [TBL] [Abstract][Full Text] [Related]
19. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease. Monji A; Takita M; Samejima T; Takaishi T; Hashimoto K; Matsunaga H; Oda M; Sumida Y; Mizoguchi Y; Kato T; Horikawa H; Kanba S Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):308-11. PubMed ID: 19138715 [TBL] [Abstract][Full Text] [Related]
20. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]